RGNX

REGENXBIO INC.

NASDAQ

Add Alert

RGNX

REGENXBIO INC.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

crudeoil24 PremiumMember

09/13/21 7:36 AM

Post #16

Re: #15: @crudeoil24 - AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie

36M share trading float.

RGNX

crudeoil24 PremiumMember

09/13/21 7:27 AM

Post #15

AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.

StockLearner2011 Free

06/03/19 9:00 AM

Post #13

https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp

StockLearner2011 Free

05/31/19 8:31 AM

Post #12

I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!

Zmill

05/28/19 9:41 PM

Post #11

is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/

BlackEyePatch Free

05/24/19 10:14 PM

Post #10

Strong buy @ 50!!!!

stocktrademan Free

08/23/18 1:16 PM

Post #9

Re: #4: @stocktrademan - RGNX bullish 14.39

RGNX buy 66.90

normal chart

log chart

StockLearner2011 Free

04/19/18 3:15 PM

Post #8

Hope no more form 4s for insider selling

StockLearner2011 Free

04/19/18 3:12 PM

Post #7

Let’s see how tomorrow will be

StockLearner2011 Free

04/19/18 3:10 PM

Post #6

Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?

StockLearner2011 Free

04/17/18 11:24 AM

Post #5

$45 soon! Yummy

stocktrademan Free

10/04/16 11:57 AM

Post #4

RGNX bullish 14.39

normal chart

log chart

protagonist12 Free

06/06/16 6:52 PM

Post #3

Re: #2: @floWteiuQ - Interesting play here for the long term. Very

Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.

floWteiuQ

05/16/16 12:19 PM

Post #2

Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.

protagonist12 Free

10/25/15 4:52 PM

Post #1

RGNX no bid support, too early still, listed VC...

REGENXBIO INC. (RGNX)

Followers	7	Posters	8
Posts (Today)	0	Posts (Total)	16
Created	10/25/15	Type	Free
Moderators

We are a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Our proprietary AAV gene delivery platform (our NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Our mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on our NAV Technology Platform. We seek to accomplish our mission through a combination of our internal development efforts and the efforts of our third-party licensees (NAV Technology Licensees). Our NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed product candidates and 18 partnered product candidates developed by our NAV Technology Licensees. Our most advanced internally developed candidates include programs for the treatment of two severe, rare genetic diseases: homozygous familial hypercholesterolemia (HoFH) and Mucopolysaccharidosis Type I (MPS I). We expect these programs to enter Phase I/II clinical trials in the first half of 2016. We also have a program for wet age-related macular degeneration (wet AMD) that is in the preclinical stage and for which we expect to file an Investigational New Drug application (IND) in the second half of 2016. We plan to build internal gene therapy franchises in the metabolic, neurodegenerative and retinal therapeutic areas, and develop multiple product candidates in these and other areas.